Randomized phase II trial of liposomal cytarabine and daunorubicin with or without pomalidomide in newly diagnosed acute myeloid leukemia myelodysplasia-related
Abstract
Not available.
// Source
Authors: Daniel T. Peters, Kristin Koenig, Anastasia Ivanova, Jiajun He, Gail J. Roboz, Uma Borate, Jesus Gonzalez-Lugo, Tara Lin, Bayard Powell, Emily Curran, Michael Hochman, Daniel Reed, Angela Nichols, Lauren Higgins, Allison McKinney, Alice Mims, William Carson, E. Claire Dees, Richard F. Little, Howard Streicher, Christopher Hourigan, Leo Luznik, Ivana Gojo, Joshua F. Zeidner
Institutions: The Ohio State University, University of North Carolina at Chapel Hill, University of Virginia, Cornell University, Emory University, Sidney Kimmel Comprehensive Cancer Center, UNC Lineberger Comprehensive Cancer Center, NewYork–Presbyterian Hospital, Presbyterian Hospital, Atrium Health Wake Forest Baptist, Virginia Tech, Baylor College of Medicine, Weill Cornell Medicine, University of Cincinnati, Augusta University Health, Piedmont Cancer Institute, The University of Kansas Cancer Center, New York Hospital Queens